Hanaki H, Labischinski H, Inaba Y, Hiramatsu K
Dept. Bacteriology, Juntendo-Univ., Tokyo, Japan.
Jpn J Antibiot. 1998 Apr;51(4):272-80.
The mechanism of resistance was studied with vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50. It was demonstrated that the incorporation of 14C-N-acetylglucosamine into the cell wall of Mu50 was not suppressed in the presence of 8 microliters/ml of vacomycin, whereas it was completely suppressed in vancomycin-susceptible strains FDA209P and H-1. Increased binding of vancomycin to the wall of Mu50 was observed compared to the control strains: 1.7 x 10(16) (Mu50), 6.1 x 10(15) (209P), and 6.7 x 10(15) (H-1) vancomycin molecules/mg cell wall, respectively. Remarkable proportion of the cell-wall component muropeptides were non-amidated in the cell wall of Mu50. In concordance with this phenomena, peptidoglycan cross-linkage decreased strikingly in the Mu50 strain. Free D-Ala-D-Ala residues at the end of muropeptides in the pre-existing cell wall generated by decreased cross-linkage seems to account for increased vancomycin binding. The increase of vancomycin-resistance level is presumably caused by sequestration of vancomycin molecules from primary target point on cell membrane. It was considered that at least two phenotypic changes are required for the vancomycin resistance in the Mu50 strain. First, as we have described previously, is the activated cell wall synthesis, and second, the reduction of cross-linkage of peptidoglycan by production of non-amidated muropeptide precursors.
利用耐万古霉素金黄色葡萄球菌(VRSA)菌株Mu50对耐药机制进行了研究。结果表明,在存在8微升/毫升万古霉素的情况下,14C-N-乙酰葡糖胺掺入Mu50细胞壁的过程未受到抑制,而在万古霉素敏感菌株FDA209P和H-1中则被完全抑制。与对照菌株相比,观察到万古霉素与Mu50细胞壁的结合增加:分别为1.7×10(16)(Mu50)、6.1×10(15)(209P)和6.7×10(15)(H-1)个万古霉素分子/毫克细胞壁。在Mu50的细胞壁中,相当一部分细胞壁成分的胞壁肽未被酰胺化。与此现象一致,Mu50菌株中的肽聚糖交联显著减少。交联减少导致的预先存在的细胞壁中胞壁肽末端的游离D-Ala-D-Ala残基似乎是万古霉素结合增加的原因。万古霉素耐药水平的提高可能是由于万古霉素分子从细胞膜上的主要靶点被隔离所致。据认为,Mu50菌株对万古霉素耐药至少需要两种表型变化。首先,如我们之前所描述的,是细胞壁合成的激活,其次,是通过产生未酰胺化的胞壁肽前体减少肽聚糖的交联。